GNI Group's Berkeley Advanced Materials Obtains U.S. Clearance for Proprietary Brand Product

MT Newswires Live09-03 13:37

GNI Group (TYO:2160) subsidiary Berkeley Advanced Biomaterials has obtained 510(k) clearance from the U.S. Food and Drug Administration for the Accelagen Plus Surgical Matrix, its first proprietary brand product, according to a Tokyo bourse filing on Thursday.

Accelagen Plus Surgical Matrix is a biomaterial-based product containing collagen and other materials used for tissue formation and natural wound healing.

The company is looking at a U.S. commercial launch for the product in the first quarter of 2027.

The 510(k) clearance allows the company to market medical devices in the U.S.

With the clearance, the company plans to grow its proprietary product portfolio and transition to this business model amid efforts to improve profitability and reach sustainable growth in the medtech segment.

Berkeley Advanced Biomaterials has historically developed and manufactured biomaterials, mainly bone graft substitutes, as well as supplied products under third party brands.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664829573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 13:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664829573","market":"hk","top_or_hot":-1,"title":"GNI Group's Berkeley Advanced Materials Obtains U.S. Clearance for Proprietary Brand Product","media":"MT Newswires Live","content":"<html><body><p> GNI Group (TYO:2160) subsidiary Berkeley Advanced Biomaterials has obtained 510(k) clearance from the U.S. Food and Drug Administration for the Accelagen Plus Surgical Matrix, its first proprietary brand product, according to a Tokyo bourse filing on Thursday.</p><p>Accelagen Plus Surgical Matrix is a biomaterial-based product containing collagen and other materials used for tissue formation and natural wound healing.</p><p>The company is looking at a U.S. commercial launch for the product in the first quarter of 2027.</p><p>The 510(k) clearance allows the company to market medical devices in the U.S.</p><p>With the clearance, the company plans to grow its proprietary product portfolio and transition to this business model amid efforts to improve profitability and reach sustainable growth in the medtech segment.</p><p>Berkeley Advanced Biomaterials has historically developed and manufactured biomaterials, mainly bone graft substitutes, as well as supplied products under third party brands.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GNI Group's Berkeley Advanced Materials Obtains U.S. Clearance for Proprietary Brand Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGNI Group's Berkeley Advanced Materials Obtains U.S. Clearance for Proprietary Brand Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-03 13:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> GNI Group (TYO:2160) subsidiary Berkeley Advanced Biomaterials has obtained 510(k) clearance from the U.S. Food and Drug Administration for the Accelagen Plus Surgical Matrix, its first proprietary brand product, according to a Tokyo bourse filing on Thursday.</p><p>Accelagen Plus Surgical Matrix is a biomaterial-based product containing collagen and other materials used for tissue formation and natural wound healing.</p><p>The company is looking at a U.S. commercial launch for the product in the first quarter of 2027.</p><p>The 510(k) clearance allows the company to market medical devices in the U.S.</p><p>With the clearance, the company plans to grow its proprietary product portfolio and transition to this business model amid efforts to improve profitability and reach sustainable growth in the medtech segment.</p><p>Berkeley Advanced Biomaterials has historically developed and manufactured biomaterials, mainly bone graft substitutes, as well as supplied products under third party brands.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZL793.SGD","symbol_name":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664829573","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664829573","pubTimestamp":1788413869,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GNI Group  subsidiary Berkeley Advanced Biomaterials has obtained 510 clearance from the U.S. Food and Drug Administration for the Accelagen Plus Surgical Matrix, its first proprietary brand product, according to a Tokyo bourse filing on Thursday.Accelagen Plus Surgical Matrix is a biomaterial-based product containing collagen and other materials used for tissue formation and natural wound healing.The company is looking at a U.S. commercial launch for the product in the first quarter of 2027.The 510 clearance allows the company to market medical devices in the U.S.With the clearance, the company plans to grow its proprietary product portfolio and transition to this business model amid efforts to improve profitability and reach sustainable growth in the medtech segment.Berkeley Advanced Biomaterials has historically developed and manufactured biomaterials, mainly bone graft substitutes, as well as supplied products under third party brands.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LU2089985449.USD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (USD) ACC","AEIS":"先进能源工业公司","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU2931357623.SGD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (SGDHDG) ACC","UYM":"基础材料指数ETF-ProShares两倍做多","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4157":"电子设备和仪器","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","LU0274383776.USD":"MANULIFE GF US SMALL CAP EQUITY \"AA\" (USD) INC"},"translate_title":"GNI 集团旗下 Berkeley Advanced Materials 获得美国自有品牌产品许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1.5,"UYM":1.5},"content_text":"GNI Group (TYO:2160) subsidiary Berkeley Advanced Biomaterials has obtained 510(k) clearance from the U.S. Food and Drug Administration for the Accelagen Plus Surgical Matrix, its first proprietary brand product, according to a Tokyo bourse filing on Thursday.Accelagen Plus Surgical Matrix is a biomaterial-based product containing collagen and other materials used for tissue formation and natural wound healing.The company is looking at a U.S. commercial launch for the product in the first quarter of 2027.The 510(k) clearance allows the company to market medical devices in the U.S.With the clearance, the company plans to grow its proprietary product portfolio and transition to this business model amid efforts to improve profitability and reach sustainable growth in the medtech segment.Berkeley Advanced Biomaterials has historically developed and manufactured biomaterials, mainly bone graft substitutes, as well as supplied products under third party brands.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664829573","isCrawlerRequest":true}